Awoyemi A, Mayerhofer C, Felix AS, Hov JR, Moscavitch SD, Lappegård KT, Hovland A, Halvorsen S, Halvorsen B, Gregersen I, Svardal A, Berge RK, Hansen SH, Götz A, Holm K, Aukrust P, Åkra S, Seljeflot I, Solheim S, Lorenzo A, Gullestad L, Trøseid M, Broch K (2021)
Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
EBioMedicine, 70, 103511 (in press)
DOI 10.1016/j.ebiom.2021.103511, PubMed 34329947

Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL, Richards AM, Lam CSP, Latini R, Staszewsky L, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD et al. (2021)
NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories
JACC Heart Fail (in press)
DOI 10.1016/j.jchf.2021.05.014, PubMed 34246607

Aukrust P, Kleveland O, Gullestad L (2021)
Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction
JACC Basic Transl Sci, 6 (5), 444-446
DOI 10.1016/j.jacbts.2021.01.007, PubMed 34102669